Macquarie Group
FOLD

Macquarie Group’s Amicus Therapeutics FOLD Stock Holding History

Macquarie Group’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-4,560,810
Closed -$35.9M – 1085
2025
Q3 		$35.9M Sell
4,560,810
-3,161,508
-41% -$22.5M 0.04% 511
2025
Q2 		$44.2M Buy
7,722,318
+907,236
+13% +$5.86M 0.05% 447
2025
Q1 		$55.6M Buy
6,815,082
+187,060
+3% +$1.73M 0.07% 384
2024
Q4 		$62.4M Sell
6,628,022
-341,857
-5% -$3.55M 0.08% 355
2024
Q3 		$74.4M Sell
6,969,879
-151,343
-2% -$1.65M 0.08% 336
2024
Q2 		$70.6M Buy
7,121,222
+50,489
+0.7% +$518K 0.08% 322
2024
Q1 		$83.3M Sell
7,070,733
-144,277
-2% -$1.85M 0.09% 268
2023
Q4 		$102M Buy
7,215,010
+2,358
+0% +$26.8K 0.12% 241
2023
Q3 		$87.7M Buy
7,212,652
+290,671
+4% +$3.75M 0.11% 249
2023
Q2 		$86.9M Sell
6,921,981
-249,054
-3% -$2.96M 0.1% 273
2023
Q1 		$79.5M Buy
7,171,035
+212,988
+3% +$2.63M 0.09% 288
2022
Q4 		$85M Buy
6,958,047
+80,286
+1% +$904K 0.1% 281
2022
Q3 		$71.8M Buy
6,877,761
+110,515
+2% +$1.23M 0.09% 313
2022
Q2 		$72.7M Buy
6,767,246
+224,367
+3% +$1.85M 0.08% 333
2022
Q1 		$62K Buy
6,542,879
+248,193
+4% +$2.33M 0.05% 451
2021
Q4 		$72.7M Sell
6,294,686
-71,898
-1% -$801K 0.06% 401
2021
Q3 		$60.8M Buy
6,366,584
+77,743
+1% +$795K 0.05% 460
2021
Q2 		$60.6M Buy
6,288,841
+594,646
+10% +$5.8M 0.05% 471
2021
Q1 		$56.3M Buy
5,694,195
+2,407,160
+73% +$37.3M 0.08% 301
2020
Q4 		$75.9M Buy
3,287,035
+2,543,281
+342% +$52M 0.11% 204
2020
Q3 		$10.5M Buy
743,754
+618,632
+494% +$9.02M 0.02% 634
2020
Q2 		$1.89M Sell
125,122
-23,448
-16% -$286K ﹤0.01% 1027
2020
Q1 		$1.37M Buy
148,570
+8,068
+6% +$76.7K ﹤0.01% 1012
2019
Q4 		$1.37M Buy
+140,502
New +$1.29M ﹤0.01% 1153

Other funds holding FOLD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Macquarie Group's FOLD Position: Q4 2025 in Review

Macquarie Group sold out of Amicus Therapeutics (FOLD) in Q4 2025, closing a stake of 4,560,810 shares — an estimated $35.9M sold.

Macquarie Group first reported a position in FOLD in Q4 2019 and held it in 24 quarters. The position peaked at $102M in Q4 2023. 332 funds tracked by Wall St. Rank hold FOLD as of Q4 2025.

  • Macquarie Group reported no remaining Amicus Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Macquarie Group sold 4,560,810 Amicus Therapeutics shares in Q4 2025, an estimated $35.9M.
  • Macquarie Group first reported a position in Amicus Therapeutics in Q4 2019 and held it in 24 quarters.
  • Macquarie Group's Amicus Therapeutics position peaked at $102M in Q4 2023.
  • 332 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q4 2025.

Based on Macquarie Group's 13F filing for Q4 2025, filed 13 Feb 2026.